| Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. (NCT04483505) | Fundacion CRIS de Investigación para Vencer el Cáncer | 2020-11-25 |
| Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer (NCT04088110) | Fuzhou General Hospital | 2019-11-01 |
| Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer (NCT04088032) | Alison Stopeck | 2019-10-01 |
| Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer (NCT04030507) | Brigham and Women's Hospital | 2019-07-26 |
| Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer (NCT03969121) | Kyoto Breast Cancer Research Network | 2019-07-16 |
| Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC (NCT03910712) | Peking Union Medical College Hospital | 2019-06-01 |
| Prospective Thinking in Hormone-Responsive Breast Cancer (NCT03594578) | Virginia Polytechnic Institute and State University | 2018-08-01 |
| Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer (NCT03088527) | Stemline Therapeutics, Inc. | 2017-10-23 |
| Comparison of the Breast Tumor Microenvironment (NCT03165487) | Columbia University | 2017-09-28 |
| Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer (NCT02668666) | Oana Danciu, MD | 2017-02-01 |
| The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population (NCT02347449) | Sunnybrook Health Sciences Centre | 2014-10-01 |
| Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab (NCT02248571) | iOMEDICO AG | 2014-08-01 |
| Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane (NCT02109913) | Amsterdam UMC, location VUmc | 2014-03-01 |
| PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score (NCT01617954) | Agendia | 2012-05-01 |
| Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer (NCT02025712) | Organisation for Oncology and Translational Research | |